Advanced Urothelial Carcinoma
Oncology·MeSH: Carcinoma, Transitional Cell
Prevalence
61.0 / 100K
Incidence
18.0 / 100K/yr
6 drugs in development·1 company·5 clinical trials
Drug Pipeline by Phase
Phase 2(5)
Phase 1(1)
| Drug | Company |
|---|---|
| TYRA-300 | Tyra Biosciences, Inc. (TYRA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Urothelial Carcinoma?
BioSniper tracks 6 drugs in development for Advanced Urothelial Carcinoma across 1 company.
How many clinical trials target Advanced Urothelial Carcinoma?
There are 5 clinical trials targeting Advanced Urothelial Carcinoma tracked by BioSniper.
What is the prevalence of Advanced Urothelial Carcinoma?
The estimated prevalence of Advanced Urothelial Carcinoma is approximately 61.0 per 100,000 population.
Deep-dive into Advanced Urothelial Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis